Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 3/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.37 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.37 |
| ▸ | PER2 | O15055 | 2/20 | 0.37 |
| ▸ | CRY1 | Q16526 | 2/20 | 0.37 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4703759 | 0.90 | PDE5A (0.41) | PDE5AMAPTKDM4EMAPK1L3MBTL1 | |
| SCHEMBL4703082 | 0.89 | ALDH1A1 (0.48) | PDE5AAKR1B1HTR6AKR1B10AKR1A1 | |
| SCHEMBL4699695 | 0.88 | MAPT (0.49) | PDE5AAKR1B1HRH1HTR6AKR1B10 | |
| SCHEMBL4699549 | 0.87 | KDM4E (0.35) | AKR1B1PTGDR2HRH1HTR6MAPT | |
| SCHEMBL4700031 | 0.86 | PDE5A (0.54) | PDE5AHTR6KDM4EALDH1A1HPGD | |
| SCHEMBL14425116 | 0.82 | PDE5A (0.43) | PDE5AHRH1HTR6MAPTKDM4E | |
| SCHEMBL4704159 | 0.78 | HSD17B10 (0.38) | PDE5APTGDR2HTR6MAPTKDM4E | |
| SCHEMBL14105155 | 0.78 | PDE5A (0.59) | PDE5AMAPTKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL4701769 | 0.76 | KDM4E (0.46) | HRH1HTR6MAPTKDM4EMAPK1 | |
| SCHEMBL4703720 | 0.76 | KDM4E (0.37) | PTGDR2PER2CRY1CRY2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390367-B1 | DIHYDROIMIDAZO 5,1-A -$G(b)-CARBOLINE DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINE | MACEF (FR) | 2008-07-09 | — | — | EP | claimed |
| US-7291627-B2 | Dihydroimidazo[5.1-a]-beta-carboline derivatives, method for their preparation, and their application as a drug | MACEF (FR) | 2007-11-06 | — | — | US | claimed |
| US-20060089372-A1 | Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine | MACEF (FR) | 2006-04-27 | — | — | US | claimed |
| EP-1390367-B1 | DIHYDROIMIDAZO 5,1-A -$G(b)-CARBOLINE DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINE | MACEF (FR) | 2008-07-09 | — | — | EP | disclosed |
| US-7291627-B2 | Dihydroimidazo[5.1-a]-beta-carboline derivatives, method for their preparation, and their application as a drug | MACEF (FR) | 2007-11-06 | — | — | US | disclosed |
| US-20060089372-A1 | Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine | MACEF (FR) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089372-A1 | Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine | GDI2, GDI1, CYP2A7 | GRIN2B 165/4885PDE5A 1728/4885AKR1B1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.